PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma

Kogashiwa, Yasunao; Yasuda, Masanori; Sakurai, Hiroyuki; Nakahira, Mitsuhiko; Sano, Yoshie; Gonda, Kenji; Ikeda, Tetsuya; Inoue, Hitoshi; Kuba, Kiyomi; Oba, Susumu; Ishikawa, Junichi; Enoki, Yuichiro; Matsumura, Satoko; Minami, Kazuhiko; Ebihara, Yasuhiro; Sugasawa, Masashi

doi:10.21873/anticanres.11465

Cited by 54 publications

(35 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coincidentally, Loeser's study 6 showed the same trend in esophageal adenocarcinoma. Moreover, we found the same trends not only in the studies of VISTA, but also in some studies of other negative immune molecules, such as PD-1 and PD-L1 [15][16][17][18][19][20] . Badoua showed that PD-1 + TILs were associated with favourable OS in human papillomavirus(+) head and neck cancer.…”

Section: Discussionsupporting

confidence: 80%

Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

Zhou

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 80%

Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

Zhou

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…After screening the title and abstract, 112 studies were excluded for their irrelevance to the topic. Finally, we included 16 studies after reviewing the full texts (11–24, 33, 34). Studies were excluded for the following reasons: six had no information about OS/DFS/PFS or reported no clinicopathological data; six had insufficient data for quantitative analysis; and two were reviews.…”

Section: Resultsmentioning

confidence: 99%

“…Some evidence supports that high PD-L2 expression in cancer specimens predicts impaired survival for various solid tumors (12–16). Nevertheless, several studies report negative results or even opposing findings (11, 17–24). Therefore, we assessed the consistency and magnitude of the prognostic effect of PD-L2 in solid cancer patients after surgery through a meta-analysis.…”

Section: Introductionmentioning

confidence: 99%

Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Background: Immune checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway are a paradigm-shifting cancer therapy. Programmed cell death ligand 2 (PD-L2) is another ligand of PD-1, but its prognostic significance in solid cancer patients after surgery remains controversial. In this study, we aimed to reveal the prognostic implication of PD-L2 in solid tumors through a meta-analysis.Methods: We searched PubMed, Embase and the Cochrane library for studies reporting the relationship between PD-L2 expression and prognosis or clinicopathological features in solid cancer patients after surgery from inception to January 2018, with language restricted to English. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were determined to explore the prognostic value of PD-L2 expression. Odds ratios (ORs) were also calculated to investigate the relationship between PD-L2 expression and clinicopathological parameters.Results: Sixteen studies incorporating 3,533 patients were included in our meta-analysis. The pooled results revealed that PD-L2 overexpression was a weak negative predictor for overall survival (OS; HR = 1.38, 95% CI = 1.05–1.81, P = 0.021), as well as a strong predictor for poor disease-free survival (DFS)/progression-free survival (PFS) (HR = 1.44, 95% CI = 1.15–1.81, P = 0.001). In subgroup analyses, high PD-L2 expression revealed an unfavorable prognostic prediction for OS in hepatocellular carcinoma (HCC) (HR = 1.60, 95% CI = 1.12–2.29, P = 0.011) and for DFS/PFS in HCC (HR = 1.50, 95%CI = 1.04–2.16, P = 0.031) as well as clear cell renal cell carcinoma (HR = 1.45, 95% CI = 1.03–2.03, P = 0.033). Moreover, PD-L2 expression implied a weak trend toward the presence of lymphatic metastasis (presence vs. absence, OR = 1.61, 95% CI = 0.98–2.65, P = 0.061).Conclusion: High PD-L2 expression may promote tumor metastasis and predict unfavorable prognosis in solid cancer patients after surgery, especially in HCC.

show abstract

“…However, in our study, higher expression of PD-L1 tended to be associated with better OS. Kogashiwa et al [35] found that higher expression of PD-L1 was associated with a higher number of CD8+ tumor-infiltrating lymphocytes, leading to better OS for HNC patients. Balermapas et al and Hanna et al [36,37] also reported higher levels of tumor-infiltrating lymphocytes in HNC patients expressing higher levels of PD-L1, which could explain the improved OS of these patients.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis

Jia

Yang

Wen

et al. 2019

Aging

View full text Add to dashboard Cite

Immune checkpoint molecules are important targets in cancer immunotherapy, but their association with prognosis in patients with head and neck cancer is controversial. In this meta-analysis, we searched for 12 immune checkpoint molecules in the PubMed, Embase and Cochrane Library databases and retrieved 52 studies with 7127 participants. Among the molecules included in the search, indoleamine 2, 3-dioxygenase (IDO), programmed death ligand 1 (PD-L1), and programmed death 1 (PD-1) met the inclusion criteria for further analysis. Higher expression of IDO was associated with poorer overall survival in head and neck cancer patients (P = 0.011), but higher expression of PD-L1 correlated with better overall survival specifically in nasopharyngeal carcinoma patients (P = 0.01). In a sensitivity analysis, higher PD-L1 expression correlated with better progression-free survival (P = 0.043), and was associated with better overall survival in Caucasian subjects (P = 0.02), nasopharyngeal carcinoma patients (P = 0.015), and studies with small sample sizes (P = 0.001). PD-1 had no prognostic significance. There was no publication bias affecting the results. Thus, among the immune checkpoint molecules, IDO and PD-L1 are potential prognostic predictors in head and neck cancer.

show abstract

PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma

Abstract: PD-L1 expression was associated with CD8 tumor-infiltrating lymphocytes and better outcome in patients with LAOSCC.

Cited by 54 publications

References 21 publications

Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis

Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis

Contact Info

Product

Resources

About